Cargando…
Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small-Cell Lung Cancer
INTRODUCTION: Tumor mutational burden (TMB) has emerged as a clinically relevant biomarker that may be associated with immune checkpoint inhibitor efficacy. Standardization of TMB measurement is essential for implementing diagnostic tools to guide treatment. OBJECTIVE: Here we describe the in-depth...
Autores principales: | Chang, Han, Sasson, Ariella, Srinivasan, Sujaya, Golhar, Ryan, Greenawalt, Danielle M., Geese, William J., Green, George, Zerba, Kim, Kirov, Stefan, Szustakowski, Joseph |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675777/ https://www.ncbi.nlm.nih.gov/pubmed/31250328 http://dx.doi.org/10.1007/s40291-019-00408-y |
Ejemplares similares
-
First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
por: Ready, Neal, et al.
Publicado: (2019) -
Reliability of dipstick assay in predicting urinary tract infection
por: Mambatta, Anith Kumar, et al.
Publicado: (2015) -
Challenges in bioinformatics approaches to tumor mutation burden analysis
por: Fenizia, Francesca, et al.
Publicado: (2021) -
Engineering bioinformatics: building reliability, performance and productivity into bioinformatics software
por: Lawlor, Brendan, et al.
Publicado: (2015) -
Metadata integrity in bioinformatics: Bridging the gap between data and knowledge
por: Caliskan, Aylin, et al.
Publicado: (2023)